MORRIS NGUYEN: Open Payments
NPI 1265839146 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,048 in 48 payments from 14 companies in 2025. Trend: 2023 $881 · 2024 $902 · 2025 $1,048
Food & beverage: $1,048
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 16 | $318 |
| Novo Nordisk Inc | 6 | $125 |
| Smith+Nephew, Inc. | 3 | $93 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| AstraZeneca Pharmaceuticals LP | 4 | $75 |
| Amgen Inc. | 3 | $74 |
| Exact Sciences Corporation | 3 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| Ascensia Diabetes Care Us Inc. | 1 | $46 |
| Astellas Pharma US Inc | 2 | $45 |
Products named: COLLAGENASE SANTYL, SPRAVATO, OTEZLA, Cologuard Collection Kit, Kerendia, Veozah, Rybelsus, FARXIGA.
Industry payments across NV — which companies pay providers there.
